Moderna and ROVI face further particulate problems with Spikevax®
A lot of Moderna’s Spikevax® vaccine is being recalled due to particulates, just six months after previous contamination concerns were supposedly solved.
List view / Grid view
News
Patent granted for thermally-controlled DNA synthesis
Evonetix has been granted a European patent for its silicon chips that leverage semiconductor technology to thermally control DNA synthesis.
Do your expectations of new supply chain technologies match reality?
Research suggests companies are often disappointed by new technologies because they have inflated expectations that do not match the tech's practical capabilities.
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm-300x278.jpg)
![Recipharm logo on building in Bordeaux, France[Credit: sylv1rob1/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Recipharm.jpg)
Recipharm builds biologics presence with acquisitions
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
Pfizer grows investigational RSV vaccine programmes with acquisition of ReViral
Pzifer's acquisition of ReViral will include its portfolio of promising therapeutic candidates, such as sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
Ultomiris of long-term clinical benefit in myasthenia gravis patients
New Ultomiris (ravulizumab-cwvz) follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
CFD airflow stimulations can help enhance cleanroom contamination control, finds study
Researchers used computational fluid dynamics (CFD) simulations to assess their cleanroom airflow and suggest improvements that would reduce contamination levels.
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
Gilead opens paediatric drug development centre in Ireland
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
FDA approves first drug for PIK3CA-Related Overgrowth Spectrum (PROS) conditions
Novartis’ Vijoice® (alpelisib) is the first and only treatment approved for the treatment of the rare spectrum of conditions associated with PROS in certain patients.
Catalent acquires new biologics facility in the UK
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
Designed for success – new SNA vaccine proves highly effective in mice
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
Big Pharma shares substance data to decrease animal testing
Four Big Pharma companies have shared previously unpublished hazard data for drug substances to enhance database-dependent computational tools and help reduce animal testing.
FUJIFILM acquires new cell therapy manufacturing facility
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
Sanofi launches pharma’s first Diversity, Equity & Inclusion Board
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Gene therapy shows promise in Wiskott–Aldrich syndrome
Lentiviral gene therapy reduces infections and bleeding episodes in children with a severe immune disorder Wiskott–Aldrich syndrome (WAS), finds new study.
